trial · primary record
Hematopoietic stem cell transplantation
Sickle Cell Disease
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | Not stated |
| Primary completion | 2027-01-25 |
| Primary endpoint | Rate of unacceptable adverse events that are defined as any of the following events that occur from start of pre-transplant immunosuppressive therapy to the first 100 days post HCT: |
| Registry ID | NCT03279094 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:46.931Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03279094
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.